Skip to main content
Equibles
RTGN logo

RTGN · RetinalGenix Technologies Inc.

Track RTGN — free

Use RTGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RTGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.99 At close · Sep 16
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company’s ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$75.19M
Shares
18.84M
Volume · Sep 16 667 Avg daily vol (1 sessions) 667

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.99 Open$4.00 Day$3.99–4.00 Available close range$3.20–4.00 Avg vol 30d1K Short int18 · 0.0% float · 1.0d Short vol100% DataFeb 2022–Sep 2026 Filing10-Q · Aug 14

The closing range uses available history since Oct 2, 2025; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$2.09M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$44
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.6%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Buy
50 / 200-day cross No cross
RSI (14) 51
neutral
52-week position 99%
near high
Momentum
relative strength
Neutral
1-month return −53%
trailing
YTD return +25%
this year
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.00% of float · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 26
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 1129%
annualized · 1-yr
Max drawdown −92%
past year
ATR 37.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 2 · 1
50 / 200-day cross
No cross Neutral
RSI (14)
51 Neutral
52-week position
99% Bullish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.00% of float · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its available closing range
Range low $3 Now $4 · 99% Range high $4

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RTGN
RetinalGenix Technologies Inc.
this stock
$75.19M — — — 0.0%
ABT
Abbott Laboratories
 $179.20B -18.2% +5.7% 33.3 0.8%
MDT
Medtronic plc
 $121.04B -1.5% +8.4% 23.3 3.1%
SYK
Stryker Corp
 $116.76B -13.4% +11.2% 31.5 1.5%
BSX
Boston Scientific Corp
 $66.02B -52.2% +12.5% 18.4 2.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest Rising
Shares short
18
Days to cover
1.0d
Change
+18 sh
View
Short Volume
Short vol %
100%
As of
Sep 21, 2026
Short Total
View
Fails to Deliver
FTD shares
18
Value
$72
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-2.4M
EPS diluted
$-0.13
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 14, 2026
This year
5
View
Proposed Sales
Value
$727.6K
Shares
181.9K
Filed
Jun 10, 2026
View
Exempt Offerings
Offering
$5.0M
Filed
Feb 11, 2025
View

Performance

5D 20D 120D MTD YTD
RTGN +6.4% -53.1% — -0.3% +24.7%
SPY -1.1% -1.8% +14.8% -1.7% +10.6%
vs SPY +7.5% -51.3% — +1.4% +14.1%
Key facts CIK 1836295 CUSIP 76133Y105 Visit website Investor relations